Home › Anemia › Ohio › Cleveland
Anemia clinical trials in Cleveland, OH
4 studies for Anemia are looking for participants at sites in and around Cleveland (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
RecruitingPhase 3
- Cleveland Clinic, Cleveland
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RecruitingPhase 1/2
- Cleveland Clinic, Cleveland
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RecruitingPhase 3
- Cleveland clinic OH, Cleveland
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
RecruitingPhase 3
- Cleveland Clinic - Cleveland, Cleveland
About Anemia
Anemia occurs when your blood doesn't carry enough oxygen to the rest of your body. Read about conditions that lead to it and treatments available.
More about Anemia on MedlinePlus
Anemia trials in other cities
- New York City, NY7 studies
- Miami, FL6 studies
- Atlanta, GA6 studies
- Philadelphia, PA6 studies
- Houston, TX5 studies
- Tampa, FL5 studies
- Winston-Salem, NC4 studies
- Baldwin Park, CA4 studies
- St. Louis, MO4 studies
- Queens, NY3 studies
- The Woodlands, TX3 studies
- Nashville, TN3 studies
Other studies in Cleveland
- Non-Small Cell Lung Cancer43 studies
- Cancer (all types)36 studies
- Breast Cancer35 studies
- Prostate Cancer34 studies
- Heart Failure33 studies
- Metastatic Cancer30 studies
- Ovarian Cancer30 studies
- Lung Cancer26 studies
- Colorectal Cancer24 studies
- Cardiovascular Disease22 studies
- Endometrial Cancer20 studies
- Acute Myeloid Leukemia20 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.